The ability of melanOlna to develop resistance to mitotoxins, growth-factor-directed anti-neoplastic agents that offer potential for the treatment of this highly refractory disease, may limit therapeutic efficacy. To address this problem, we developed a subcloned human melanoma cell line that is resistant to the mitotoxin composed of basic fibroblast growth factor conjugated to the ribosome-inactivating protein saporin. Resistance was caused by autocrine FGF ligands, which down-regulate bFGF receptors and reduce bFGF-saporin binding. Inhibiting the auto-T he mitotoxin basic fibroblast g rowth factor (bFGF)-saporin is a hybrid cytotoxic prote in composed of bFGF covalentl y coupl ed to a ribosomal toxin that offers a novel approac h for the treatment of n eoplastic disease . T hi s mitotox in attac hes to the cell -surface g rowth factor rece ptor via the li gand and internalizes by receptormediated e nd ocytosis; upon its release into the cy topl as m by the lower pH of the endoso m e, the saporin moiety ca.tal ytica Lly in.b.ibits protein synthesis by rend erin g th e 60-S subunit of riboso m es un able to bind elongation facto r 2, th us m ediatin g cell death [1] . T lus approach m ay h ave therap e utic utility for the trea tm e nt of malignant melanoma, in part beca use bFGF rece pto r expression in most nonproliferating normal cell s appears to be very limited [2] and beca use m any melanoma cell lines express hjg h-affiluty receptors for bFGF [3] . G ive n th e refractory nature of melanoma to traditio nal therap y and the potent cytotoxicity of bFGF-saporin that we and othe rs ha ve demonstrated fOf melano ma cell s both in vitro and ill Vi llO for xen ograft and m etastati c m o dels [4, 5] , bFG F-saporinmay o ffer a n ew strategy in che m otherapy.
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As with conv ention al chemotherape uti c agents, however, effective treatm ent m ay be limi ted by th e em erge nce of res ista nt tumor cell populations. T umors eve ntu all y fec ur in xenografted mjce, and up to 40% appea r resistant to furth e r therapy with b FGF-saporin (unpublish ed o bservations). As bFGF-sapori.n mov es closer to Manu script received November 7, 1994 ; lin al revisio n received Febru ary 17, 1995; accepted for publi cation Febru ary 23, 1995. R.eprint requests to Dr. A. R.a ym o nd Fracke lton, Jr, Department of Medicin e, R.oger Williams Medi ca l Center, 825 C halkstone Avenu e, Providence, IU 02908.
• clinical trials, it becom es in creasin g ly important to und erstand resista nce and to devise strategies for combating ,resistance. B eca use production of mitotoxin-resistant cell s has bee n describ ed by other investigators [6-9], these strategies might be widely app lica ble to other mitotoxin co nju gates or immunotoxin conjugates as w ell. W e report he re that subpopulations of human melanoma cells escap e bFGF-saporin targeting becau se of a bFGF auto crin e loop, and we provide e viden ce that t1u s endogeliolls bFGF downregulates bFGF receptors on these cells, thus redu cing their availabi li ty for nutotoxin binding and subseq uent cytotoxi city . W e demonstrate that t1us mode of res ista nce may be circ umvented by usin g age nts such as suramin or ne utrali zing antibodies to FGF, whic h block the alltocrine loop and up-reg ulate receptors, be fore treatment with bFGF-sa po rin to restore sen sitivi ty ill villo and ;11 lIitro .
MATER.1ALS AND METHODS
Mitotoxin bFGF-sa porin wa s a generou s gift from D.A. Lappi and A. Baird (Th e Whittier In stitute, La J olla, CAl. Saporin was conju gated to bFGF usin g N-succinimidyl-3(2-pyrid ydithi o) pro prionate, and the conjugate was purifi ed by hepa rin-sepharose and chromatography, as described L 10,1 1).
Dcvclopmcnt and Cloning of bFGF-Saporin-Rc.istant CcIls SK-MEL-5 cells (American Type C ul ture Coll ection, Rockvi lle, MD) were subjected to increasin g selectiv e pressure ill lIilro using a procedure adapted from Teicher and Frei [1 2] . Briefly, semi conflu ent SK-MEL-5 cell s gro wing in minimum essential mediul11 (G ibco-BRL, Grand Island , NY) suppl emented with 10% fetal bovin e se rum (Gibco-BRL) and antib iotics were trea ted overnight with 10 nM bFGF-sa porin (suffi cient to kill approximately 90% of the cdls). After treatment, th e ce ll s were washed three times with phosphate-buffered sa line (PB S), £i'esh m edium was added, and incubati o n of cells was contin ued . Each tim e the cells rea ched app roxima te ly 75% confluence, bFG F-sa porin was adm ini stered in a dose escalated 15' \1" Ii'o m the prev io us treatment. When o vernight treatment with 40 nM bFGFsaporin wa s rea ched , survivin g cell s were recovered and grow n in medium suppl emented with 10% feta l bov in e serum and 2 nM bFGF-saporin to 
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maintain se lective pressure. After "pproximately I year of treatment. includin g 1 m onth of growth in the constant prese nce of bFGF-saporin. resista nt ce ll s were cloned by limi ting dilution w ithout bFGF-saporin . One colony. FSB4. w"s expanded in the absence of bFGF-sa porin selective press ure for 2 months. Subseq uent bFGF-saporin survival assays revealed that it had reta ined resistance desp ite the absence of selective pressure. Do ublin g time for the FSB4 clone was approximately 18 h, compared w ith approximHtely 22 h for the parental SK-MEL-5.
Colony Formation Assay Subconllu ent ce ll monolayers, seeded Ht a con centration of 2 X :10' cells/cm 2, we re mHin tained ove rni gh t in supplem e nted minimu111 essentia l medium as above. T he fo ll owin g day, the cells were washed with medium and th en exposed to b FGF-sap orin (5-150 nM) or sa porin (25-1000 nM ) for 1 h in serum-free medium. After treatment, the cell s were washed three times with fresh medium. suspended by treatment w ith trypsin /ethylened iHm ine tetraacetic acid , and reseeded at 3 X 10 3 ce ll s/cm 2 in dup li cate. After 7 d, colon ies were co un ted . Results arc r epo rted as the conce ntration of bFGF-saporin or saporin tha t resulted in 50'% reducti on in colonies. Results from three independent experiments were paired by treatmen t and analyzed using the pHired Wilcoxon test (Instat; GrHph Pad, Sa n D iego, CA) . [1 3] . Cell extracts (from equivalent n umbers of ce ll s) we re resolved by 7'Yo sod ium dodecylsu lf.1te polyacrylamid e ge l electrophoresi s (SOS-PAGE) und er reducing conditions. and bFGF recepto rs were visualized by autoradiograp hy using Kodak XAR-5 presensitized fi lm with Lightning Plus intensifying screens at -70°C for 1-8 d.
bFGF R eceptor Assay 12s l_bFGF bindin g was performed usin g a radioreceptor assay as described by Moscatelli [14) . Briefly. ce lls growin g in six-we ll plates were washed with PBS and in cubated with serum-free D ulbccco's modified Eagle's medium conta ining O. I S% ge latin and 25 mM HEP ES (N-2-hydroxyethylpiperazine-N ' -2-ethanesu lfoni c acid) (PH 7.4) fo r 1 h at 37°C. Afte r 1 h , the m ed ium was repla ced w ith fresh m edium co ntainin g 125 I_bFGF (S-SO ng/ ml). After 2 h at 4°C on a platform rocker. th e cell s were washed o nce w ith co ld PBS and twice w ith 2 M NaC I in 20 mM HE PES (pH 7.4) to remove 125 1_bFGF bound to extracellul ar matrix (low-affinity recepto rs) (1 4). 125I_b FGF bound to high-attlni ty receptors was r e leased by two subsequent washes w ith 2 M NaCI in 20 mM sodium acetate (pH 4 .0). Nonspecific binding was determ in ed in th e presence of SOO-fo ld excess of unlabeled bFGF. R eleased radioactivity wa s quantitated in a gamma scintillatio n counter (MULTI-PKI AS; Packard Instrument. Sterlin g, V A).
bFGF Competition Assay SK-MEL-S and FSB4 cells were seeded into 96-well tissue cul ture plates (Costar, C ambridge, MA) at 10 3 cells/well. T he next day. th e med ium was removed and medi um containing bFGFsaporin (1-5000 pM) or bFGF-saporin with 100-fold excess bFGF (0.1-500 nM) was added to the we lls. Ce ll s in tripli cate well s were c ultured for 72 h w ith bFGF-sapo,-in. Surviving cell s were counted using a Co ulter Co unter (Cou lter Electronics. Inc ., Hialeah, FL).
Detection of b FGF Rec eptor Proteins Receptor proteins were purified from 5 X 10(' cell s by mi crobatch afri ni ty chromatogra ph y on the C-l S po lyclona l jig an tibody (specific for FGFKI ; Sa n ta C ru z Biotechno logy, Inc ., Santa C ru z, CA), lin ked to sepharose beads, solubilized by boiling in sodium dodecylsu lf.1te (SOS) samp le bufFer w ith redu cing re"gents, and resolved by 7.5% SDS-PAGE. The receptor proteins we"e transferred to nitrocellul ose filters and incubated with C-1 S antibod), (2 p.g/ ml) , the fi lters were washed. and bound protein s w ere visuali zed by enhau ced chemiluminescence. as directed by the man ufacturer (A mersha m) . As a control, SK-MẼL-5 cell s w ere in cubated with peptide sc-121P (Santa C ruz Bi otechnology. In c. ) capable of blocki ng anti~j1g bind ing.
Suramin and Nentralizing Antibodies in Cell Snrvival Assays Medium on subconfluent mo no layers of parenta l o r res ista nt cells was rep laced with fres h serum-fi'ee medium with or witho ut suramin (1 mM) (FBA Pharma ceutica ls, New York, NY) or neutrali zing antibod ies (10 mg/ I) to bFGF (Upstate B iotechn ology, In c., LIke Placid . NY) and /or to acid ic FGF (aFGF) (K&O Systems, Minneapolis. MN). Fifteen h ours later, th e medium was removed and the cel ls were washed tlu'ee times with un suppl emented medium before exposin g cells to bFGF-saporin (5-1S0 nM) fo r 1 h in serum-free medium. After treatment, the cell s were pro cessed as in the co lon y assays described above, except that indi vid ual ce ll s were counted. It.esults from three independent experim ents were anal yzed by the paired Wilcoxon test usin g In stat.
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Detection of b F GF Intracellnlar and Extracellnlar Protein To detect intracellu lar bFGF, w e isolated bFGF from extracts of80% confluent cultures of parent and resistant cells using affinity chromatography on bFGF monoclonal antibody (Santa Cruz Biotechn ology. In c.) that had been covalently coupled to Protein A Sepharose CL-4B (Phannacia LKB Bioteclm o logy, Inc.) u sing dimethylpemilimidate (Sigma) . To detect extracellul ar bFGF. cultures of parent and resistant cell s were serum starved for 8 h and then in cuba ted overnight in serum-free m edium with bFGF-neutralizing antibody (UB I) covalen tly coupled to Protein A Seph arose CL-4B. b FGF was elu ted from the immunosorbcnt as above. T he intrace llul ar and extracellular sampl es of bFGF and. as a control, 1 ng ofhumaJl reco mbinant bFGF (Amersham), were reduced and alkylated (with 0.2 M N-ethylmaleimide [1 5]) before resolving the proteins by 12% SDS-PAGE. T he proteins were transferred clectrophoretically onto nitrocellul ose (Hybond; Amersham). which was probed using antibody to bFGF (2 p.g/ml) (Santa Cruz Biotechn ology, In c.) and visualized by chemi luminescence as above.
I" Vivo Antitunlor Stndies Cell s from parental and resistant I.ines growing in culture w ere implanted subcutaneously into the ri ght rear flanks of8-week-old male Balb/c nu / n u mice at a concentration of2 X 10" ce ll s in 0. 1 ml of unsuppl emented minimum esse ntia l medium on day O. Nude mice were bred and maintained by the Roger W illiam s Cancer Center Animal Care Faci li ty in accordan ce with institutional guidelines. For a.ll studies, b FGF-saporin was dissolved in steri le pBS/O. 1 0;., bovine serum albumin, and treatment (31-125 p.g/kg) was delivered by in tr>1Venous tail injection 5 d after implan tation , when the tumors were approximately 50 mm 3 • For studies combining bFGF-saporin with suramin. surami n was disso lved in sterile PBS. and treatm ent (150 mg/ kg) was delivered by intravenous tail inj ection on days 1-3 before bFGF-saporin treatment (62 f.l,g /kg) on day S. T he progress of each tumor was measured at least twice weekly, and tumor volumes were calculated using the fOn1ml a: Volume = [(minimum m easu rement)2 (maximum measurement)] /2 [16] . Median tumor vo lum es for the various treatment grou ps were compared by Instat using the Krll ska l-Wallis nonparametri c test, fo ll owed by Dunn post-tests to compare th e effects of vario us treatments.
RESULTS
Development of an SK-MEL-5 Subclone Resistant to bFGFSaporin [/I II j/m, a bFGF-saporin resistant cell lin e was dev e loped b y system atic dose escalatio n a nd was clon ed b y limiting di lu tion.
Cell surv iva l was d etermine d in colo n y-formation assays for parental SK-MEL-5 and the cloned resistant sub lin e. FSB4, exposed to va ri o u s concentratio n s ofbFGF-saporin o r saporin aJone . The 50% inhibi to ry con centration (IC so ) (150 nM) for bFGF-saporin in cloned FSB4 ce ll s was sixfo ld hig h e r than th e IC so (25 nM) for the parental SK-MEL-5 cell li.ll e (p < 0.01). Treannent w ith saporin a lone demonstrated o nl y minim a l cytotOl";city, with ICsos of 900 nM o r g r eater in b oth cell lin es; t h e FSB4 resistant lin e d e monstrated a sligh t in crease in sensiti v ity comp ared with the parenta.! line. By co lo n y-form a ti o n assays. sen sitiv ity to bFGF-saporin returned g radu a ll y over 3-5 m o n t h s in th e absence of se lective pressure (data not sh own).
The Resistant Clone Displays Fewer bFGF Receptors Prelimin ary studies ha ve su ggested a direc t correla tion between t h e sensitiv ity of cell s to bFGF-saporin and the number of FGF receptors per cell [1 0] ; therefore, we hypoth esized that bFGFsaporin resistance might b e attri buted to reduced expression ofFGF receptors . To test this h ypoth esis, we cross-linked 125 J_bFGF to FGF r eceptors with DSS . SDS-PAGE an a lysis revealed a broad. 1.45-170-kDa b aJ~d (Fig 1) con siste n t in size w ith that expected for bFGF c ross-linked to FGF r eceptors [17] . Den sitom etric ana.!ysis of this band in three re p eated experime nts sh owed 0% to 25% as much receptor in FSB4 clone d cell s as in th e parental SK-MEL-5 cell lin e . We o b served an interesting in c r ease in hi g h-afrinity bFGF receptors that parall e led t h e loss of resistance during prolonged (3-5 month s) c ulture in the absence of b FGF-sa p orin selective pressure, consistent w ith o ur d evelo ping h ypoth esis that a d ecrease in FGF receptor numbers was resp ons ible for bFGF-saporin resistance.
By 12SI_bFGF radioreceptor assay, parental SK-MEL-5 cell s h ad approximately 23,000 hi g h -affinity binding sites per cell by Scatc hard a n a lys is [1 8 ] , simil ar to prev ious ly deternlined va lues [3] . Con sistent with the redu c ed receptor cross-linkin g of FSB4 cells (Fig 1) and t h e ir r edu ced 125 1_bFGF binding, t h e resistant cell s (Fig 2B) .
Exogenons bFGF Renders the Parental Cells Insensitive to bFGF-Saporin and Down-Regulates bFGF Receptors It is interesting that a 100-fold excess of bFGF, which com p etes with bFGF-saporiJl for binding to FGF receptors [9] , shifted the parenta l survival curve (p < 0.002) to nearly coin cide with that of the FSB4 cell s (p > 0 .05) (Fig 3A) . In lig ht of these results and because autocrine bFGF has a major role in the transformation and growth of melanoma cell s [19] , we h ypoth esized that excessive bFGF produced by FSB4 cell s mi ght be down-regu lating bFGF receptors. Consistent with this possibility, chroni cally exposin g parental cell s to exogeno u s bFGF down-regulated receptors, an effect that co uld be reversed within 24 h by remov in g the exoge nous bFGF from culture ( Fig 3B) . (Fig 4) . By pulse cha se ana lys is, the 90-kDa protein appeared to be a precursor of the 130-kDa and lSO-kDa receptor prote ins, whereas th e 110-kD" protein appeared to be a degrad ation prod uct of th e mature, lS0-kDa and 130-kDa bFGF receptors (data not shown) . inte n sity of th e 150-kDa receptor while d ecreasin g intensity of the 130-kDa rece p tor and the 1l0-kDa " degradation " product. Consiste nt with b oth these d ata and o ur d evelopin g hy p oth esis of autocrin e -drive n resistance to bFGF-saporin , pretreatment with suramin had littl e e ffect on th e bFGF-saporin sensitiv ity of pare ntal cell s ill lIil.ro. H owever, suramin reduced by approximately 60-fold t h e con centration of b FGF-sa p orin re quire d to yie ld a 50% inhibitio n in FSB4 survi val (Fig SA) (p < 0 .0001). It is n oteworth y that this re nd ered FSB4 cell s nearly 10 times more sensitive than parental cell s to bFGF-s aporin.
To d etermine whether suram in mi g h t b e exertin g its effects b y compl exin g with auton'ine b FGF, we tested w h e ther' n e utral izing antibody to bFGF would similarl y restore bFGF-saporin sensitiv ity to FSB4 ce lls. SK-MEL-5 and FSB4 cell s w e re treated overnight with n e u tra li z in g antibody sp ccifr c for hum an b FGF, wash e d , and then treate d with bFGF-sa p o rin . T his pretreatmen t iJl c reased th e bFGF-sa p orin se n sitivity of FSB4 cell s so that th e ir 7-d surv ival c urv e was indistin g uish able liOln that of the parental cell tin e ( Fig   SB) (p > 0.1) . Taken togeth er, t h ese resul ts suggest tha t sura min 's ability to restore bFGF-sap orin sen siti v ity to resistant FSB4 ce Us occ urs, at least in part, from its ab ili ty to bl ock th e interactio n b etween end ogeno u s bFGF and its rece ptor. However , resistant cell s pretreated with bFGF n e utrali z in g antibod y did not d e m o nstrate the h ype rse n sitivi ty engendered b y suramin . Perhaps tlle resistant ce Us constitutiv ely secreted an oth er g rowth factor in addi tio n to bFGF ca pable of co mpe tin g for bFGF receptors. A likely candidate is aFGF, inas mu ch as both aFGF and b FGF bind w ith hig h aftinity to FGF receptor type-l (fig) and to FGF rece ptor typ e-2 (bek) [24] . A lth o u g h pre trea tm e n t of pare ntal SK-MEL-5 cells with n e u tra lizing an tibody to bFGF did n ot allect th e ir se n sitivi ty to bFGF-sa p orin , pretreatme nt with n e u tra li z in g antibod y specific for aFGF in creased th e ir sensiti vity, su gges ting th at aFGF partially inhibi ts bFGF-sa p o rin bindin g and cytotoxi c ity in pare ntal cell s (Fig SB) . Similarly, pre treatm e nt of FSB4 resista n t cells w ith neutrali z in g antibody to aFGF in creased th e ir sensitiv ity to b FGFsapo rin severa lfo ld (p < 0.0001) . Combinin g n e u tra liz in g antibodies to aFGF and b FGF for pre treatm e n t of FSB4 cell s furt h e r in creased FSB4 sen siti v ity (p < 0 .0001) , co mparabl e to FSB4 cell s treate d w ith suramin and to parental cell s treate d with n e utrali z in g antibody to aFGF alone or the co mbina tio n of n e utra li z in g antibodies to aFGF an d bF G I~. T h ese findin gs suggest that both pare n ta l and resistant c ells pro du ce au toerinc FGFs; h owever, though
Comparison of Endogenous bFGF in Resistant and Parental
Cells T h ese results also su ggested th at resistant FSB4 cell s som eh ow diffe r in their expressio n of bFG F compar ed with pa.rental SK-MEL-5 ce Us. To in vestigate tlus fu r th er, we purifie d b FGF from SK-MEL-5 o r FSB4 cell s by immu noaffin ity c hroma togra ph y a.nd an alyzed it by immunoblotting. A n IS-kDa band co-mig r atin g with hum an recombin ant b FGF was detected in both the parent and resista n t li n es (Fig 6) . In ad dition, 22-and 24-kDa b ands representin g bFGF arising fro m an alternative translation-initiation site [2 5 ] were also d e tected . Densitometric anal ysis of th e b 3Jlds suggested that resistant FSB4 expressed o nl y 35% m ore total bFGF th an pare n ta l ceUs, with n o relative c han ge in isoform expression. These observation s su ggest an ove raU increase in bFG F production or in its stability as opposed to th e u se of a m ore efficie nt initiation codon [25] in th e FSB4 cell s; h oweve r , it remains to b e ascerta ined c o A.
SK-MEL-5 FSB4 whether the observed increase in intrace llul ar bFGF I S alone responsible for the resistant phenotype. JO or thi s reason , we next examined the presence of bFGF in cond iti oned m e dia. Secreted bFGF was captured by in c ubating monolayer cultures ofSK-MEL-5 or FSD4 cell s overnight with neutralizing an tibody to bFGF, and the immune complexes were ana lyzed by anti-bFGF immunoblotting. bFGF proteins h ad mol ecular weights of 16, 18, 22, and 24 kDa, and an ad ditional higher mo lecular weigh t form not observed in intracellul ar assays was detected at approximate ly 30 kDa in both parental SK-MEL-5 and FSD4 cell s (Fig 7) . Densitometric ana lysis of bFGF proteins reve aled that FSD4 secreted 20% to 30% more 18-kDa and 30-kDa bFGF, but 40% less 22-kDa bFGF th an parent ce ll s. Wheth er th ese d ifferences represent a switch to a more biologically active isofornl in the resistant FSB4 cell s is not known. We asked next w hether su ram in wo uld simil arly restore bFGFsaporin sensitivity in FSB4 resistant cell s ;11 vivo. Nude mi ce bearing parental SK-MEL-5 xenografts or FSB4 xe n ografts, which retain resistance to bFGF-saporin (31-125 /.Lg/kg) ;11 V;I/O (Fig SA) , were treated with suramin intravenously for 3 d b efore a single intravenous inj ection of bFGF-sa porin 5 d after tumor implantation. Suramin treatment of anima ls with FSD4 xenografts restored bFGF-saporin sensitivity (Fig SB) . This was seen as a greater than 60% reduction in FSB4 tumor vo lum es as of day 30 after implantation, compared w ith tumor volumes of FSD4-bearin g animals receiving bFGF-saporin treatment alone (p < 0.05). [n con trast, suramin treatment alone did n ot sign ificantly affect th e growth of either SK-MEL-5 or FSB4 xenografts co mpared with ve hi clettea ted controls. T hirty days after t um o r implantatio n , th e median tumor volumes of bFGF-saporin-treated SK-MEL-5 xenografts 111eas ured 22% of ve hicl e-treated control tUIn o rs, demonstrating appJ:oximate ly fourfold g reater sc n sitiv ity to b FGF-saporin compare d w ith FSD4 resistant xen ografts (p < 0.0l) . Suramin trea tment of SK-MEL-5 xen ograft-bearin g ani mals resul ted in initial bFGFsaporin-mediated tum or reduction co mparabl e to that demonstratcd in an ima ls rece iving bFGF-saporin treatm e nt alone. HoweveJ:, by day 30, these tum ors were more than twice as large as tumors in an im als receiving bFGF-saporin alone (p < 0.05).
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DlSCUSSION
Tn su mmary, ch ron ic exposure of SK-MEL-5 hum an melanoma ce Us to bFGF-sapotin provided th e selective pressure that resu lted in ou r d evelo pme nt of b FGF-saporin res istant cell s, fi:om which th e FSB4 sub)jn e was cloned. T h e FSD4 line sh owed a sixfold d ecrease in bFGF-sap01;n sen sitivity (by IC so ) co mp ared with th e parental line in colo ny-form ation assa ys and pron o un ced res istance in nude mouse xenografts . The resistance of FSB4 is du e to extra cellular autoCl'in e loops between aFGF, bFGF, and cellular receptors for bFGF; these loops down-reg ulate bFGF receptors and thus favor survival of this variant when treated with bFGF-sapori.n . Of course, one mi g ht find independ e ntl y isolated subclones that are resistant Ilia non-autocrine mechanisms. Based on the theories developed by Coldman and Go ldi e [26] desc ribin g the gene ti c instability of neoplasms and th e favored survival of phenotypic or genetic variants that are res istant to partic ular dru gs, it is in retrospect not surprising that prolonged expos ure of SK-MEL-S cell s to bFGFsa porin selected for this resi stant subpopulation. Studies presente d
here confirm that bFGF-saporin resistant cell s developed ;11 II;tro maintain resista n ce ;11 11 ;110, and subsequent studies are c urre ntly und erway to develop bFGF-sa porin resistance ;11 1) ;110 to de te rtnil1 e whether resistance arises from the same m ec hanism in both mod els.
In vestigations of bFGF-saporin dosing regime ns ;11 I);IJO suggest th e importance of frequent adlTtinistration for optimal therapeutic responses:I' Beca use prolonged exposure to bFGF-saporin ;11 1) ;1) 0 may simi larly select resistance, investigating bFGF-saporin resist;U1 ce and the mech anisms by which it occurs may be cruci al to developing th e rapeuti c regimens that will prevent or circumvent bFGF-saporin treatm ent failure in neoplastic disease .
Fina]]y, the ability of suramin to restore ;11 1) ;11'0 sensitivity to bPGF-saporin in res istant FSB4 cells through disruptiol. l of the bFGF autocrine loop, as indicated by re sults obtained using nelltrali zing antibodies to bFGF ;11 11;11'0, suggests that both suramin and neutraljz ing antibodies have potential use in combined-modality therapy with bFGF-saporin. Preliminary ;11 1) ; 1)0 expe rim ents presented here de m o nstrate that suramin is al so effective in restol;ng sensitivity to bFGF-sapo rin in FSB4 xe nog rafts; however , whether the mechanism ;11 1) ;1)0 is the same as w e hav e determined for the ill 1) ;1,.0 model has yet to be examined. B es ides the ab ility to bloc k re ceptor-liga nd interactions, suramin can inhibit DNA topois011l erase II , ce rtain tyrosine phosphata ses, and lysosomal enzymes [27] [28] [29] , anyone of whjch ma y influen ce mitotoxin sensitivity. Lappi el al have re ported that bFGF-saporin cytotox icity is inhjbited in the presen ce of suramin ;11 1) ;11'0 [10]; th e decrea sed sensitivity of parental xenografts treated with the combination of suramin and bFGF-sa porin suggests that an antagonisti c association m ay exist between these agents ;11 1) ;1)0 as well , which minimizes persistent anti-tumor activity of bFGF-saporin . Alte matively, suramin ma y promote malignant cell prolifera tion by activating an autocri.11e loop involving transforming growth £1ctor-cy and epidermal growth factor receptors [30], both of whic h are fo und in malignant melanoma [31 ,32] and tumor vasc ulature. W e are currently optimizing th e rape utic efficacy for preventing and circumventing resistan ce in malig nant m elanoma by using multiple cycles of surami.n follow ed by bFGF-sa porin . 
